149484-90-2 Usage
Uses
Used in Pharmaceutical Industry:
1-(2-phenylethyl)-3-(1,3,4-thiadiazol-2-yl)thiourea is used as a potential therapeutic agent for its antifungal, antibacterial, and antitumor properties. The presence of the phenylethyl and thiadiazolyl groups in the compound may contribute to its effectiveness in treating various medical conditions.
Used in Medicinal Chemistry Research:
1-(2-phenylethyl)-3-(1,3,4-thiadiazol-2-yl)thiourea serves as a subject of interest for medicinal chemistry research due to its potential biological activities. The study of its structure-activity relationship and optimization could lead to the development of new drugs with improved efficacy and safety profiles.
Used in Drug Design and Development:
1-(2-phenylethyl)-3-(1,3,4-thiadiazol-2-yl)thiourea is used as a starting point for drug design and development. Its unique structure and known biological activities make it a valuable template for creating new molecules with enhanced properties for various therapeutic applications.
Check Digit Verification of cas no
The CAS Registry Mumber 149484-90-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,9,4,8 and 4 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 149484-90:
(8*1)+(7*4)+(6*9)+(5*4)+(4*8)+(3*4)+(2*9)+(1*0)=172
172 % 10 = 2
So 149484-90-2 is a valid CAS Registry Number.
149484-90-2Relevant academic research and scientific papers
Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs
Bell,Cantrell,Hogberg,Jaskunas,Johansson,Jordan,Kinnick,Lind,Morin Jr.,Noreen,Oberg,Palkowitz,Parrish,Pranc,Sahlberg,Ternansky,Vasileff,Vrang,West,et al.
, p. 4929 - 4936 (2007/10/03)
A novel series of potent specific HIV-1 inhibitory compounds is described. The lead compound in the series, N-(2-phenethyl)-N'-(2-thiazolyl)thiourea (1), inhibits HIV-1 RT using rCdG as the template with an IC50 of 0.9 μM. In MT-4 cells, compound 1 inhibits HIV-1 with an ED50 of 1.3 μM. The 50% cytotoxic dose in cell culture is >380 μM. The chemical structure-activity relationship (SAR) was developed by notionally dividing the lead compound in four quadrants. The SAR strategy had two phases. The first phase involved optimization of antiviral activity through independent variation of quadrants 1-4. The second phase involved the preparation of hybrid structures combining the best of these substituents. Further SAR studies and pharmacokinetic considerations led to the identification of N-(2-pyridyl)-N'-(5-bromo-2- pyridyl)-thiourea (62; LY300046 · HCl) as a candidate for clinical evaluation. LY300046 · HCl inhibits HIV-1 RT with an IC50 of 15 nM and in cell culture has an ED50 of 20 nM.
